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EXPERIMENTAL STUDIES
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After Myocardial Infarction in the Dog Model
Effects of Reperfusion, Amlodipine and Enalapril
Bodh I. Jugdutt, MD, FACC,* Vijayan Menon, BSC,* Dinender Kumar, PHD,* Halliday Idikio, MD†
Edmonton, Alberta, Canada
OBJECTIVES We sought to determine whether reperfusion and the calcium channel blocker amlodipine or
the angiotensin-converting enzyme inhibitor enalapril, during healing over six weeks after
myocardial infarction (MI), limit structural vascular remodeling in the noninfarct zone (NIZ).
BACKGROUND The effect of reperfusion and amlodipine or enalapril on structural vascular remodeling during
healing of MI has not been determined.
METHODS We randomly assigned 54 dogs to reperfused or nonreperfused MI, followed by twice-daily
doses of oral placebo, amlodipine (5 mg) or enalapril (5 mg) for six weeks and three days off
treatment, or to three matching sham groups. We measured in vivo hemodynamic data and
left ventricular (LV) function and remodeling (by echocardiography) over the six weeks, as
well as ex vivo structural vascular, ventricular and collagen remodeling in the hearts after six
weeks.
RESULTS Compared with placebo and sham groups, both amlodipine and enalapril with or without
reperfusion produced LV unloading and limited structural LV remodeling and dysfunction
over six weeks in vivo, and also decreased the NIZ resistance vessel media/lumen area ratio
at six weeks ex vivo. In addition, amlodipine, but not enalapril, preserved infarct scar collagen
and increased the border zone collagen volume fraction and perivascular fibrosis, as well as
NIZ resistance vessel media thickness. Enalapril, but not amlodipine, decreased transforming
growth factor-beta in the border zone and NIZ.
CONCLUSIONS The results indicate that therapy with amlodipine and enalapril during healing after
reperfused MI limits structural vascular remodeling in the NIZ, probably by different
mechanisms. (J Am Coll Cardiol 2002;39:1538–45) © 2002 by the American College of
Cardiology Foundation
We hypothesized that therapy applied to limit structural left
ventricular (LV) remodeling during healing after reperfused
myocardial infarction (MI) (1) should modify structural
vascular remodeling (2,3) in the noninfarct zone (NIZ).
During healing after MI, increased collagen in the infarct
zone (IZ) (1,4,5) and NIZ (1,5), together with NIZ
hypertrophy, contributes to decreased LV distensibility (6)
and diastolic dysfunction. Left ventricular hypertrophy in
hypertensive patients is associated with an increased arte-
riolar wall thickness area, peri-arteriolar fibrosis, interstitial
fibrosis and impaired coronary reserve (7). Coronary reper-
fusion after MI limits LV structural remodeling (8), but
results in “reperfusion injury” (9), less IZ collagen (8),
reduced nitric oxide release and coronary flow reserve (10).
Angiotensin-converting enzyme (ACE) inhibitors produce
many clinical benefits and limit LV dilation after MI (11),
and also decrease collagen in the IZ (11) and NIZ (12) and
in resistance arterioles in hypertensive patients (13,14). The
new calcium channel blocker amlodipine improves survival
in patients with nonischemic cardiomyopathy (15), limits
LV dilation after infarction in dogs (16), rats (17) and
cardiomyopathic hamsters (18). Both amlodipine and ACE
inhibitors modulate kinin-mediated nitric oxide production
in canine (19) and human (20) coronary microvessels, and
also decrease the media thickness of resistance arteries in
spontaneously hypertensive rats (13,14). Prolonged treat-
ment of post-infarction rats with amlodipine induces vas-
cular changes in the NIZ and improves the survival of rats
with small infarcts (21). The aim of this study was to
determine whether reperfusion and amlodipine or enalapril,
during healing over six weeks after MI, limit structural NIZ
vascular remodeling in association with LV structural and
collagen remodeling in the dog.
METHODS
Experimental preparation. The studies were approved by
the institutional Animal Welfare Committee and con-
formed with the “Position of the American Heart Associ-
ation on Research Animal Use,” adopted by the Association
in November 1984. Fifty-six healthy mongrel dogs (weight
17 to 22 kg) were instrumented through a left lateral
thoracotomy, under general anesthesia (sodium pentobarbi-
tal, 30 mg/kg intravenously), as described previously (8).
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Briefly, indwelling catheters were inserted in the external
jugular vein, internal carotid artery and left atrium for
monitoring hemodynamic variables. The mid-left anterior
descending coronary artery was tied with a silk ligature.
Visible epicardial feeders at the margins of the occluded bed
were ligated to produce transmural injury (16). Metal beads
were sutured on the epicardium of the mid-LV wall for
consistent orientation of two-dimensional echocardiograms.
Reperfusion (n  19) was produced by removing the
ligature 2 h after coronary occlusion. No ligations were
made in 18 animals (sham group). The pericardium and
chest were closed. Penicillin (1 million U) and streptomycin
(1 g) were then given intramuscularly.
Protocol. Twenty-four hours later (day 2), 54 surviving
animals with or without reperfused MI (one dog in each
arm died) were randomized (2  3 factorial design) to three
treatment groups (n  6 per cell)—twice-daily oral placebo,
amlodipine (Pfizer Canada Inc., Dorval, Quebec; 5-mg
tablet) or enalapril (Merck Frosst Inc., Dorval, Quebec;
5-mg tablet) for six weeks—and three matching sham
groups (n  3 per cell). The doses of amlodipine and
enalapril were previously confirmed to decrease the mean
blood pressure by 10% at 4 to 6 h after oral administration
on the second day after MI (16). After six weeks of therapy
and three days off therapy, the animals were re-anesthetized
and a thoracotomy was performed, and the hearts were
arrested in diastole (1 mol/l of potassium chloride intrave-
nously), quickly excised, washed in saline solution and
weighed.
In vivo measurements. As described previously (8), quan-
titative two-dimensional echocardiograms (Hewlett-
Packard, Sonos 1000; 3.5- or 5-MHz transducer, Palo Alto,
California), electrocardiograms (Gould recorder, Cleveland,
Ohio) and left atrial and arterial pressures (Gould P23Db)
were simultaneously recorded in the conscious animals on
day 2, before therapy; on day 3 and weekly over six weeks of
therapy; and three days after stopping therapy. The two-
dimensional echocardiographic images were coded, ana-
lyzed off-line by two observers, in blinded fashion, and
digitized (Hewlett-Packard Vectra 486/33T computer;
Summagraphics-Summasketch III, Seymour, Connecticut)
for LV remodeling and functional variables (8,16), includ-
ing the diastolic endocardial surface area of asynergy,
systolic and diastolic volumes, global ejection fraction,
expansion index, thinning ratio, diastolic bulge of the IZ,
global shape index (16) and LV mass.
Ex vivo measurement of scar size and LV geometry. As
described previously (6,8,16), the risk regions were mea-
sured from postmortem coronary arteriograms of fresh
hearts (using simultaneous injection into each coronary
artery with a barium sulfate and gelatin mixture, under
constant pressure of 160 mm Hg) and were recorded on
radiographs of the formalin-fixed whole heart and five
equally spaced transverse sections (1- to 1.5-cm thick).
Fixation involved suspension in 10% phosphate-buffered
formalin, 10 cm below the surface for 48 h. Outlines of LV
rings, risk regions and infarct scars were made on plastic
overlays and planimetered (Hewlett-Packard Vectra 486/
33T computer; Summagraphics-Summasketch III) for in-
farct scar size and topographic variables, including the
thinning ratio and expansion index (6,8,16).
Measurement of collagen content and collagen volume
fraction (CVF). Myocardial hydroxyproline (mg/g dry tis-
sue weight), a marker of collagen protein, was measured, as
described previously (4,8,11), in 100-mg tissue samples
from the center of the IZ (occluded bed) and NIZ (left
circumflex territory) in the third LV ring. For CVF, samples
from the IZ, NIZ, spared zone within the risk region and
border zone outside the risk area of the fourth LV ring (Fig.
1) were embedded and sectioned, as described previously
(22). Sections (4-m thick) were stained with 1% picro-
sirius red for fibrillar collagen (23) and examined under a
Nikon (Tokyo, Japan) Labophot II microscope (200 mag-
nification) fitted with cross-polarization filters and a high-
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CVF  collagen volume fraction
IZ  infarct zone
LV  left ventricular
MI  myocardial infarction
NIZ  noninfarct zone
PVF  perivascular fibrosis
TGF  transforming growth factor
Figure 1. Diagram showing the method used for tissue sampling. LAD 
left anterior descending coronary artery; LCX  left circumflex coronary
artery; LV  left ventricular.
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resolution digital color camera (Sanyo VCC-3770, Tokyo,
Japan). Perivascular and interstitial collagen appeared red,
and the remaining tissue appeared yellow. Interstitial colla-
gen density was analyzed (Leco 2001 image analyzer,
Longueuil, Quebec) by excluding perivascular fibrosis (PVF)
and infarct scar, and was expressed as percent myocardial area.
Assessment of vascular remodeling. Sections from the IZ,
NIZ and border and spared zones of the fourth LV ring
were examined in blinded fashion by an experienced ob-
server. Perivascular fibrosis was scored 1 to 5 semiquantita-
tively on sets of coded slides stained with picrosirius red or
trichrome, and the average of the two scores was calculated.
Planimetric analysis of blood vessels on the picrosirius-red
slides was carried out using camera-produced Lucida draw-
ings (130, 260 and 520 magnifications) that were
digitized on a graphics tablet (Summagraphics-
Summasketch III) for the area and perimeters of the vessel
wall and lumen, as well as the wall/lumen ratio. Average
values were computed for each section. Only blood vessels
with area 5 to 20  104 m2 and a form factor—computed
using the formula (24): F  4  A/P2, where A  lumen
area and P  perimeter—of F  0.75 were included. The
media/lumen ratio was plotted against the total blood vessel
area, using a nonlinear curve fitter or power regression
algorithm (Jandel Scientific Inc., San Rafael, California).
Photographs were taken and scanned (Digital Science
Photo CD software, Eastman Kodak Co., Rochester, New
York).
Transforming growth factor-beta (TGF-beta). To deter-
mine whether changes in TGF-beta might explain the
changes in collagen and PVF, histologic tissue sections (5
m) from the NIZ, IZ and border zone of the hearts from
the placebo, enalapril and amlodipine groups were immu-
nostained by Dr. Kumar using the cell and tissue staining
indirect immunoperoxidase kit (R&D Systems, Minneapo-
lis, Minnesota), according to the manufacturer’s instructions
(25), with primary polyclonal pan-specific rabbit antibody
and secondary biotinylated anti-rabbit antibody. The sec-
tions were analyzed by Dr. Idikio, using a microscope
(Olympus BH-2), and TGF-beta staining was scored from
0 to 3.
Statistics. Data were analyzed in blinded manner, using
analysis of variance with repeated measures and multiple
comparisons (Student-Neuman-Keuls test) for the signifi-
cance of differences within and between groups and for
comparing serial data within groups. Results are presented
as the mean value  SEM. Statistical significance was set at
p  0.05.
RESULTS
In vivo hemodynamic data and LV function and remod-
eling. At baseline (day 2), all variables were similar in the
sham and infarct groups, and, compared with the sham
group, the infarct groups showed increased left atrial pres-
sure and clearly different LV function and geometry. With
amlodipine and enalapril with or without reperfusion over
six weeks, the heart rate, mean arterial pressure, left atrial
pressure and rate–pressure product all decreased, compared
with baseline values (p  0.05 to 0.001), and left atrial
pressure persistently decreased (p  0.001) three days after
the active drugs were stopped, compared with placebo.
Compared with the nonreperfused placebo group six weeks
after MI, total LV asynergy increased in all reperfusion
groups (33% vs. 16%, p  0.05); the thinning ratio was
lower in all treatment groups (59% vs. 37%, p  0.05)
and actually increased in the nonreperfused amlodipine
group (59% vs. 10%, p  0.001); the expansion index
increased slightly in the reperfused enalapril and amlodipine
groups (2.4% vs. 13%, p  0.05); the diastolic and systolic
volumes decreased in all treatment groups (p  0.05 to
0.01); the global LV ejection fraction improved in the
reperfused placebo group (6% vs. 18%, p  0.01) and in the
nonreperfused enalapril and amlodipine groups (6% vs.
32%, p  0.01); the LV mass decreased in all treatment
groups (24% vs. 2%, p  0.001); and both the global shape
index (8% vs. 2%, p  0.005) and regional IZ bulging
(86% vs. 7%, p  0.02) decreased with amlodipine.
Infarct scar size and collagen protein. At six weeks, the
infarct scar size in the nonreperfused placebo group (30 
2% risk region) was larger than that in the reperfused
placebo (16  4%, p  0.05) and enalapril (15  2%, p 
0.05) groups or in the nonreperfused amlodipine (18  4%,
p  0.05) and enalapril (13  3%, p  0.001) groups. The
hydroxyproline content (mg/g) in the IZ decreased from
45  8 in the nonreperfused placebo group to 27 6 in the
reperfused group (p  0.05), to 21  4 in the amlodipine
group with or without reperfusion (p  0.01), to 9  2 in
the enalapril group with or without reperfusion (p 0.002).
Compared with the sham group, NIZ hydroxyproline
(mg/g) increased from 3.6 0.3 to 6.4 1.0 in the placebo
group (p 0.007) and to 4.9 0.5 in the amlodipine group
(p  0.03), but not in the enalapril group (4.1  0.7).
Collagen volume fraction (Figs. 2A and 2B). Compared
with the sham group, interstitial CVF increased signifi-
cantly in the spared zone of the nonreperfused groups; the
increase was most pronounced with amlodipine. Compared
with placebo, CVF showed a mild increase in the border
zone of the reperfused amlodipine group.
Perivascular collagen (Figs. 2C and 2D). Compared with
the placebo and enalapril groups, amlodipine increased PVF
in the nonreperfused spared zone and the reperfused border
zone. Amlodipine also increased PVF (p  0.05) in the
noninfarcted interventricular septum and remote right ven-
tricular regions in the reperfused and nonreperfused groups
(data not shown).
Vascular remodeling in the NIZ (Figs. 2E and 2F). Data
on the media/lumen ratio and media thickness for the
reperfused and nonreperfused groups were pooled, as they
were similar. Compared with the sham group, the media/
lumen ratio increased in the placebo group and normalized
in the spared and border zones and NIZ in the amlodipine
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Figure 2. Effect of treatments on CVF (A, B), PVF (C,D) and the media/lumen ratio and media thickness (E,F). Data on vessels with areas 5 to 20 
104 m2 are shown and pooled for hearts with or without reperfusion (E,F).
and enalapril groups (Fig. 2E), and the media thickness
increased in the spared and border zones and NIZ in all
treatment groups (Fig. 2F). The NIZ media thickness with
amlodipine was greater than that with placebo and enalapril
(Fig. 2F).
Vessel size. Power function plots confirmed that an in-
creased media/lumen ratio was mainly related to remodeling
of small vessels, with an area 20  104 m2, and the
regressions were slightly lower (p  NS) in the sham,
enalapril and amlodipine groups than in the placebo group
(Fig. 3). The increased ratio with placebo was due to an
increase in the area of the media and a mild decrease in the
lumen size, whereas the decreased ratio with amlodipine was
associated with an increase in lumen size and media thick-
ness (Fig. 4). The decreased ratio with enalapril was
associated with a decrease in media thickness, compared
with placebo, but was similar, relative to lumen size, to that
with amlodipine (Fig. 5).
Transforming growth factor-beta. Compared with the
placebo group, the TGF-beta score in the NIZ myocardial
and perivascular regions decreased with enalapril (0.3 vs.
1.5), but not with amlodipine (2.3 vs. 1.5). Staining of
TGF-beta was found mainly in cardiomyocytes, vascular
smooth muscle cells and fibroblasts.
DISCUSSION
The results of this study indicate that significant remodeling
occurs in resistance vessels of the NIZ in healed reperfused
and nonreperfused hearts, with an increase in the media
thickness and media/lumen ratio of the remote NIZ and
border zone. Importantly, enalapril and amlodipine both
normalize the media/lumen ratio in resistance vessels of the
NIZ. However, this effect seems to involve different mech-
anisms, as the media thickness of the vessels in the NIZ
increased with amlodipine, but not with enalapril. In addi-
tion, TGF-beta in the NIZ decreased with enalapril, but
not with amlodipine.
Importance of NIZ vascular remodeling. To the best of
our knowledge, structural vascular remodeling in the NIZ
during healing after reperfused infarction, or its limitation
by therapy, has not been reported previously. Studies of rats
Figure 3. Power function plots of the media/lumen ratio versus blood vessel area. Data were pooled for hearts with or without reperfusion. Note the cluster
of points at the lower area range (20  104 m2). Regression coefficients (r) were 0.83 for the sham group, 0.59 for the placebo, 0.75 for the amlodipine
group and 0.33 for the enalapril group.
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have shown that the NIZ undergoes hypertrophy, which is
associated with decreased coronary flow reserve (26). The
hypertrophy triggered by MI is most intense at the border
zone and about a week after infarction, while vascular
growth lags behind (2). The stimulus may be provided by
neurohormonal activation (27) and release of angiotensin II
(28), catecholamines, endothelin, fibrogenic growth factors
such as TGF-beta, cytokines and other active molecules.
Healed and remodeled post-infarction rat hearts show an
impaired vascular reserve in the hypertrophied NIZ and a
perfusion deficit in the border zone (2). The hypertrophied
NIZ is therefore considered to be at increased risk of
ischemic injury under stress, so that protective therapy
might be desirable.
In this study, we found a quantitatively significant and
similar increase in the media/lumen ratio and media thick-
ness of the resistance arteries in the NIZ of both reperfused
and nonreperfused placebo-treated hearts, compared with
the sham group. Although we did not assess the functional
significance of the structural changes under stress, these
changes might explain the impaired vascular reserve re-
ported in the NIZ (26). Although the vascular remodeling
paradigm in LV hypertrophy associated with hypertension
is also “increased wall thickness/lumen diameter (or wall/
lumen) ratio,” it was suggested that there was a rearrange-
ment of the existing material around a smaller lumen,
without much growth (29). In contrast, growth plays a
major role in the remodeling of cardiac vessels, ventricles
and collagen matrix during post-infarction healing. Our
finding of increased TGF in the NIZ of control animals, as
well as its attenuation by enalapril (but not amlodipine),
suggests the observed changes in media thickness, PVF and
interstitial fibrosis may involve angiotensin II and TGF-
beta. Further studies of TGF-beta isoforms, cell types and
signaling and the possible role of the kinin–nitric oxide
pathway are needed to clarify the precise mechanism.
Limitations of NIZ vascular remodeling. One goal of
treatment of structural vascular remodeling is normalization
of the vascular structure (29). In this study, six weeks of
therapy with amlodipine or enalapril normalized the media/
lumen ratio in the NIZ resistance vessels, compared with
the sham group. This vascular effect was associated with
previously reported, overall beneficial effects of reperfusion
(8), ACE inhibition (11) and amlodipine (16) on LV
structural remodeling and dysfunction, suggesting that it
might have contributed to these benefits. However, the
effects of amlodipine and enalapril on different variables of
both LV and vascular remodeling after reperfusion were
complex. Importantly, the decrease in the media/lumen
ratio in the NIZ was not accompanied by a decrease in
media thickness. In fact, media thickness in NIZ vessels 1)
remained increased in all treatment groups, compared with
sham; 2) was similar with enalapril and placebo; and 3) was
actually greater with amlodipine, compared with placebo,
enalapril and sham. The underlying explanation was that
the lumen size showed a relatively mild increase with
enalapril and a relatively more marked increase with amlo-
dipine (Fig. 5). We are not aware of other reports on the
limitation of remodeling of small resistance arteries in the
Figure 5. Diagram showing changes in the resistance vessel lumen (inner
circle) and wall (area between inner and outer circles). The dark area
represents perivascular fibrosis. The wall/lumen ratio is nearly similar for
enalapril and amlodipine, although the wall area is less with enalapril and
greater with amlodipine, compared with placebo.
Figure 4. Typical photomicrographs of noninfarct tissue six weeks after
myocardial infarction. Picrosirius-red staining shows collagen as red, and
myocytes and other structures as yellow. A2, B2  polarized light showing
collagen as bright yellow or green; A1, A2  placebo effect; B1, B2  effect of
amlodipine, showing a resistance vessel with an increased area of media,
relative to the lumen, and perivascular fibrosis. Arrows indicate vessels.
Crystalline material from postmortem arteriograms are seen within the lumen.
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NIZ by an ACE inhibitor or calcium channel blocker after
MI.
Previous studies. In hypertensive patients, an increased
intramyocardial vessel wall area and PVF are associated with
impaired vasodilatory reserve (7), and the ACE inhibitor
cilazapril, administered over two years, decreases the media/
lumen ratio of resistance arteries in gluteal fat biopsies. In
spontaneously hypertensive rats, the ACE inhibitor perin-
dopril produces dose-dependent regression of resistance
coronary artery remodeling (30), and enalapril (10 mg/kg)
or amlodipine (10 to 20 mg/kg) for 12 weeks produce
regression of resistance coronary artery remodeling and a
decrease in the media/lumen ratio (13). Because angiotensin
II regulates cytosolic calcium in vascular smooth muscle,
Sharifi et al. (13) speculated that enalapril and amlodipine
might exert similar effects on vascular remodeling. In our
infarcted hearts, we also found that amlodipine and enala-
pril decreased the media/lumen ratio, but amlodipine in-
creased the media thickness of resistance arteries in the
NIZ, although enalapril did not.
In post-infarction rats treated with amlodipine (5 mg/kg)
for nine months, Whittaker et al. (21) found a similar
increase in NIZ resistance coronary artery media thickness
and PVF, as in our study, and speculated that the
amlodipine-induced increase in media thickness and PVF
might resist vessel compression and maintain flow (21).
However, neither they (21) nor we measured regional
coronary blood flow or vascular reserve with stress, so that
the true functional significance of the structural resistance
vessel remodeling in the NIZ remains to be studied. At rest,
no differences in NIZ flow (2) or total LV flow (3) were
detected in rat hearts after infarction. Whittaker’s (21)
findings of a decreased lumen diameter, increased media/
lumen ratio, no change in NIZ collagen and myocyte
cross-sectional area differ from ours, but this might be
related to the dose and longer exposure to amlodipine in
their study, as well as differences in the severity of remod-
eling between rats and dogs (5). Using a higher dose of
amlodipine (10 mg/kg) in post-infarction rats, Shimada et
al. (17) showed attenuation of both the increase in LV mass
and NIZ collagen messenger ribonucleic acid, as suggested
in our study. It is possible that regional differences in the
intensity of the growth response exist between the rat and
dog models.
In support of our findings, amlodipine and enalapril have
prevented LV remodeling and NIZ fibrosis in cardiomyo-
pathic hamsters (18); amlodipine (31) and ACE inhibitor
therapy (12) have decreased NIZ fibrosis in post-infarction
rats; and angiotensin II type 1 receptor blockade (32), but
not amlodipine (33), has decreased TGF-beta1 in kidney
models.
A pertinent technical feature of our study is that all hearts
were arrested in diastole and had postmortem arteriograms
and fixation in distention. This systematic approach pre-
served not only the diastolic proportions of the chambers,
but also the vessel shape (preventing collapse and distortion)
during formalin fixation. In addition, all drug treatments
were stopped three days before the hearts were removed, so
as to minimize the possibility of persistent pharmacologic
effects on vascular tone.
Conclusions. In this study, therapy with reperfusion fol-
lowed by enalapril or amlodipine for six weeks after infarc-
tion limited structural vascular remodeling in the NIZ, with
a decrease in the resistance vessel media/lumen ratio. This
effect was associated with overall beneficial effects on struc-
tural LV remodeling and function, and may be clinically
important. The functional significance of the vascular
changes in the NIZ and whether they contributed to the
limitation of ventricular remodeling and dysfunction with
enalapril and amlodipine need further study.
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